Targets › LMNA
1 program from 1 company in 1 trial: 1 Phase 1; Cardiovascular; next expected readout Mar 2030.
[Lamin-A/C]: Lamins are intermediate filament proteins that assemble into a filamentous meshwork, and which constitute the major components of the nuclear lamina, a fibrous layer on the nucleoplasmic side of the inner nuclear membrane. Lamins provide a framework for the nuclear envelope, bridging the nuclear envelope and chromatin, thereby playing an important role in nuclear assembly, chromatin organization,…. (UniProt, P02545)
Open in Phaseline: the race on LMNA, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Nuevocor Pte. | NVC-001 Gene therapy targeting LMNA mutations | LMNA | Phase 1 | LMNA-Related Dilated Cardiomyopathy | Mar 2030 |
LMNA-Related Dilated Cardiomyopathy (1)
other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.